Inhaled Corticosteroids and Sickle Cell Disease Severity in Adults Without Asthma: A Randomized Clinical Trial.

What was studied

This trial tested daily inhaled mometasone in adults with sickle cell disease. They had cough and wheeze but no asthma diagnosis. In all, 77 people were analyzed. Of these, 40 got mometasone and 37 got placebo. Treatment lasted 48 weeks. The main measure was the change in VCAM-1, a marker of disease severity.

What they found

VCAM-1 levels rose more in the mometasone group than in the placebo group. Clinical outcomes leaned toward placebo. These gaps were not statistically significant. The mometasone dose was 220 μg once daily. Mean age was 36.0 years with mometasone and 31.5 with placebo.

What it means for patients

The authors say long courses of inhaled mometasone were linked to worse disease markers. They state it should not be used long-term in these adults. This is for people with sickle cell disease, cough and wheeze, and no asthma diagnosis.

Why it is not certain yet

The trial analyzed 77 people. Clinical gaps were not statistically significant. The abstract does not give the size of the clinical gaps. The results apply to adults with no asthma diagnosis.

Source

Inhaled Corticosteroids and Sickle Cell Disease Severity in Adults Without Asthma: A Randomized Clinical Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.